Are immune checkpoint combination therapies for intermediate and poor risk renal cell carcinoma better than immune checkpoint inhibitors combined with kinase inhibitors

2021 
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []